We are proud to announce that Wald Biotech is taking a significant step forward — bringing our full range of Walzym and LymfoVeno Walzym products to the Slovak market starting May 15, 2026. This expansion marks a major milestone in our mission to make our premium products accessible to patients and healthcare professionals across Central Europe.
A Natural Next Step
Since our establishment in the Czech Republic, Wald Biotech has built a strong reputation for quality, innovation, and a patient-first approach. Our Walzym and LymfoVeno Walzym product lines have earned the trust of healthcare professionals and customers alike, and demand from neighbouring Slovakia has been growing steadily. Expanding across the border is not just a business decision — it is a response to a genuine need in the Slovak healthcare market.
Slovakia shares not only a border with the Czech Republic, but also a deeply connected medical community, a similar healthcare infrastructure, and patients facing the same challenges that our products are designed to address. Entering this market feels like a homecoming as much as an expansion.
Official Launch at “XIV. Lymfologický deň v Piešťanoch”
We are honoured to officially introduce Wald Biotech to the Slovak professional community at one of the most respected medical events in the region — XIV. Lymfologický deň v Piešťanoch (Lymphology Days) in Piešťany. This prestigious conference brings together leading lymphology specialists, physiotherapists, and healthcare professionals from across Slovakia and beyond, making it the ideal platform to present our product portfolio.
Our team will be present at the event to meet with specialists, answer questions, and discuss how Walzym and LymfoVeno Walzym can support their patients in practice.
What Slovak Customers Can Expect
From May 15, 2026, Slovak customers and healthcare providers will have access to the complete Walzym and LymfoVeno Walzym portfolios, with distribution details to be announced closer to the launch date. We are committed to ensuring the same level of availability, product quality, and customer support that our Czech customers have come to rely on.
We are currently establishing partnerships with key Slovak distributors and pharmacy networks to ensure a smooth and accessible rollout across the country from day one.
Looking Ahead
The Slovak expansion is a cornerstone of Wald Biotech’s broader growth strategy in Central Europe. We see enormous potential in bringing science-backed, high-quality biotechnology products to markets where patient care is paramount and demand for trusted solutions continues to rise.
“Slovakia has always been a key part of our long-term vision. We are excited to finally bring Walzym and LymfoVeno Walzym to Slovak patients and healthcare professionals, and Lymfologické Dni in Piešťany is the perfect stage to begin that journey.” — J. Chmelař, CEO, Wald Biotech
We look forward to welcoming Slovak customers, partners, and healthcare professionals into the Wald Biotech family. Stay tuned for further announcements on distribution, availability, and our presence at upcoming Slovak medical events.
